Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Intangibles (2018 - 2023)

Sangamo Therapeutics (SGMO) has disclosed Intangibles for 8 consecutive years, with $51.6 million as the latest value for Q1 2023.

  • For Q1 2023, Intangibles fell 2.13% year-over-year to $51.6 million; the TTM value through Mar 2023 reached $51.6 million, down 2.13%, while the annual FY2022 figure was $50.7 million, 5.64% down from the prior year.
  • Intangibles hit $51.6 million in Q1 2023 for Sangamo Therapeutics, up from $50.7 million in the prior quarter.
  • Across five years, Intangibles topped out at $58.1 million in Q4 2020 and bottomed at $46.4 million in Q3 2022.
  • Average Intangibles over 5 years is $53.1 million, with a median of $53.2 million recorded in 2019.
  • Year-over-year, Intangibles increased 9.35% in 2020 and then decreased 15.45% in 2022.
  • Sangamo Therapeutics' Intangibles stood at $53.2 million in 2019, then grew by 9.35% to $58.1 million in 2020, then decreased by 7.51% to $53.8 million in 2021, then fell by 5.64% to $50.7 million in 2022, then increased by 1.63% to $51.6 million in 2023.
  • According to Business Quant data, Intangibles over the past three periods came in at $51.6 million, $50.7 million, and $46.4 million for Q1 2023, Q4 2022, and Q3 2022 respectively.